Helicobacter Pylori Infections
Helicobacter pylori (H. pylori) is a spiral-shaped, flagellated gram-negative bacterium colonizing the human stomach that usually infects the stomach and small intestine. It is one of the most common chronic bacterial infections worldwide, usually acquired during childhood, yet most infected individuals remain asymptomatic.
Helicobacter Pylori Infections Epidemiology Segmentation in the 7MM
- Diagnosed Prevalent Cases
- Gender-specific Diagnosed Prevalent Cases
- Age-specific Diagnosed Prevalent Cases
Helicobacter Pylori Infections Epidemiological Insights Observed in the 7MM (2021)
The total number of incident cases of Helicobacter Pylori Infections observed in the 7MM was observed to be 321 million in the year 2021
The Helicobacter Pylori Infections epidemiology based on gender-specific diagnosed prevalent cases in the United States accounted for 57 million cases in Females and 62 Million cases in Males
Helicobacter Pylori Infections Market Insight
The market size of Helicobacter Pylori Infections in the 7MM was found to be approximately USD 1,564 million in 2021.
Helicobacter Pylori Infections Market Strengths
Several regimens such as bismuth, sequential therapy, concomitant therapy, and others have become available which will help improve the treatment and overcome the limitations of first-line Clarithromycin-based triple therapy.
Helicobacter Pylori Infections Market Opportunities
Considering the high prevalence of H. pylori infection, there is a tremendous opportunity for pharma companies to develop prophylactic or therapeutic vaccines for H. pylori.
Helicobacter Pylori Infections Emerging Drugs and Key Companies
- Finafloxacin: MerLion Pharmaceuticals/Bayer
- Tegoprazan/RQ00000004: RaQualia Pharma/HKinno.N
- SCG321: SCG Cell Therapy
- R435/R529: Recce Pharmaceuticals
- Oral Aroeira/Amoxicillin/Claritromycin: Infan Industria Quimica Farmaceutica Nacional
- Linaprazan glurate: Cinclus Pharma
- SQ109: Sequella
- SVT-1C4610: Servatus
- Ceclezepide: TrioMedicine